drugset / Trial / NCT03928262
Pharmacokinetic Study of Benralizumab in Healthy Chinese Subjects
RandomizedParallel-groupTriple-blindTreatment
Summary
This is a Phase 1, randomized, single-blind study in healthy Chinese subjects at single dose administration of benralizumab: Treatment 1, Treatment 2 and Treatment 3. The study design allows an assessment of 3 doses with safety monitoring and PK sampling to evaluate the safety, tolerability and PK profile of benralizumab.
Timeline
- Start
- 2019-04-02
- Primary completion
- 2019-08-12
- Completion
- 2019-08-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Benralizumab | Monoclonal antibody | — | Subcutaneous |
Indications
No indication recorded.